Edmund Mickunas Named Vice President of Regulatory for Advanced Cell Technologies

WORCESTER, Mass., Aug 10, 2009 (BUSINESS WIRE) --
ACTC | Quote | Chart | News | PowerRating -- Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC),
announced today that it has hired Edmund Mickunas as Vice President
Regulatory. Mr. Mickunas will be in charge of spearheading the company's
effort to translate its cutting edge research into FDA approved
therapies ready for clinical trials. Specifically, Mr. Mickunas will
work with Dr. Robert Lanza and ACT's Development Team to finalize and
submit an IND for the RPE program to the FDA for approval to commence a
Phase I Clinical Trial. Mr. Mickunas has over 28 years of experience
across a breadth of disciplines including the biotechnology, medical
device and pharmaceutical fields. During his career he has worked in
preclinical program development, clinical affairs, regulatory
affairs/compliance and quality assurance, and has worked closely with
all disciplines involved in product development. Prior to joining
Advanced Cell, Mr. Mickunas was Executive Director, Regulatory Affairs
and Quality Assurance for Applied Genetic Technologies Corporation, a
privately held gene therapy and genomics-focused biotech company.

Before joining Applied Genetic Technologies, he was Vice President,
Regulatory, Quality and Clinical Affairs for Oragenics, a company
engaged in the development of vaccines, biologics and pharmaceuticals.
Mr. Mickunas was previously Senior Director of Regulatory Affairs and
Compliance for Control Delivery Systems, Inc., where he managed the
submissions of IND filings, among other responsibilities. He also held
senior regulatory positions at Bioheart, Inc., Cytomed and Del
Laboratories. He received his B.S. and pursued graduate studies in human
biochemistry at Fairleigh Dickinson University, as well as a Masters
Degree from Fairfield University.

"We are pleased that Ed has elected to join us as his extensive
regulatory expertise and experience in filing IND's will be invaluable
as we prepare to file our first IND with the FDA in the second half of
this year," said William M. Caldwell IV, Chairman & CEO of Advanced
Cell. "Ed's most recent assignment focused on retinal programs. He has
strong relations with the Ophthalmology Departments of our clinical
advisors as well as recent first hand experience with processing retinal
IND applications through the FDA. We look forward to his input and to
his role in helping to move our stem cell therapeutic programs into and
through the clinical process."

Before joining Applied Genetic Technologies, he was Vice President,
Regulatory, Quality and Clinical Affairs for Oragenics, a company
engaged in the development of vaccines, biologics and pharmaceuticals.
Mr. Mickunas was previously Senior Director of Regulatory Affairs and
Compliance for Control Delivery Systems, Inc., where he managed the
submissions of IND filings, among other responsibilities. He also held
senior regulatory positions at Bioheart, Inc., Cytomed and Del
Laboratories. He received his B.S. and pursued graduate studies in human
biochemistry at Fairleigh Dickinson University, as well as a Masters
Degree from Fairfield University.

"I look forward to joining ACT at such an exciting time in the Company's
development," said Mr. Mickunas. "I am impressed that despite a
challenging economic and political environment, the Company has been
able to acquire and develop such a promising regenerative medicine
platform and to advance it to an industry leading stage of clinical
development. I feel very privileged to be working with Dr. Lanza, a well
respected leader in the field of regenerative medicine and Mr. Caldwell,
whose financial experience is setting the Company on sound footing to
make the clinical development of these very significant biotechnology
platforms possible."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying
cellular technology in the field of regenerative medicine. For more
information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future ability to draw on
the credit Facility, future financial and operating results, future
growth in research and development programs, potential applications of
our technology, opportunities for the Company and any other statements
about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans,"
"anticipates," "expects," "estimates," and similar expressions) should
also be considered to be forward-looking statements. There are a number
of important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements,
including: the Company's ability to meet all of the conditions to allow
it to access the entire amount available under the credit Facility
discussed in this press release, limited operating history, need for
future capital, risks inherent in the development and commercialization
of potential products, protection of our intellectual property, and
economic conditions generally. Additional information on potential
factors that could affect our results and other risks and uncertainties
are detailed from time to time in the company's periodic reports,
including the report on Form 10-K for the year ended December 31,
2009. Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made, and
the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made, and
the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

CEOcast, Inc. 
Dan Schustack, 212-732-4300

For full details on (ACTC) ACTC. (ACTC) has Short Term PowerRatings at TradingMarkets. Details on (ACTC) Short Term PowerRatings is available at This Link.